NKT

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Retrieved on: 
星期四, 四月 25, 2024
Natural killer T cell, NKT, GRI, Doctor of Philosophy, LIVE

LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.

Key Points: 
  • LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE!
  • with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Retrieved on: 
星期二, 四月 16, 2024
Natural killer T cell, IP, IPF, KIPO, GRI, Doctor of Philosophy, Idiopathic disease, NKT, RAR, Patent, Retinoic acid, Oxygen, Liver, Patient, Treatment, Movement, Idiopathic pulmonary fibrosis, Interim, Pharmaceutical industry

LA JOLLA, CA, April 16, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled, "Prevention and Treatment of Inflammatory Conditions."

Key Points: 
  • The issued patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells in the prevention and treatment of inflammatory conditions of the liver.
  • “We are pleased to add this Korea patent to our intellectual property portfolio covering our innovative pipeline of NKT cell modulators.
  • Each granted patent provides further validation and bolsters our confidence of our differentiated approach to the prevention and treatment of inflammatory, fibrotic and autoimmune diseases.
  • For more information about the Company’s innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, visit gribio.com .

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

Retrieved on: 
星期一, 四月 8, 2024
GRI, Natural killer T cell, NKT, Conference

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.

Key Points: 
  • LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.
  • Details of the presentation are as follows:

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 四月 1, 2024
Research, Conference, Lupus, Inflammation, Patient, Food and Drug Administration, CTA, Doctor of Philosophy, SLE, Insurance, GRI, IPF, Fibrosis, Oxygen, Immune system, Injury, NKT, Food, Movement, Lupus nephritis, Autoimmune disease, Natural killer T cell, Medication, Pharmaceutical industry

LA JOLLA, CA, April 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the fiscal year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
  • GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells.
  • Research and development expenses were $3.2 million and $0.2 million for the years ended December 31, 2023 and 2022, respectively.
  • General and administrative expenses were $8.2 million and $2.0 million for the years ended December 31, 2023 and 2022, respectively.

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Retrieved on: 
星期四, 三月 28, 2024
GRI, Natural killer T cell, NKT, Conference, Doctor of Philosophy

LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET.

Key Points: 
  • LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET.
  • In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website .

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

Retrieved on: 
星期四, 三月 14, 2024
Retinoic acid, Patient, CIPO, Doctor of Philosophy, Idiopathic pulmonary fibrosis, GRI, IPF, RAR, Treatment, Oxygen, Patent, Interim, NKT, Idiopathic disease, Liver, Movement, Natural killer T cell, Pharmaceutical industry

LA JOLLA, CA, March 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,007,970 titled, "Prevention and Treatment of Inflammatory Conditions." A patent from the recently allowed application is expected to be issued in the coming months.

Key Points: 
  • A patent from the recently allowed application is expected to be issued in the coming months.
  • “We have remained committed to bolstering our intellectual property protection across our innovative pipeline of NKT cell modulators.
  • IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
  • For more information about the Company’s innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, visit gribio.com .

Nektr Launches Airdrop and Raffle dApps Amid Recent Rebranding

Retrieved on: 
星期一, 三月 4, 2024
Polygon, Chain-link fencing, Commerce, MATIC, Non-fungible token, NFT, Airdrop, CSV, Ecosystem, NKT, Cryptocurrency

Des Moines, Iowa, March 04, 2024 (GLOBE NEWSWIRE) -- Nektr (‘nek-ter) , a Polygon-based token offering Web3 business and commerce solutions, announced the release of two new decentralized applications (dApps) as part of its recent rebranding.

Key Points: 
  • Des Moines, Iowa, March 04, 2024 (GLOBE NEWSWIRE) -- Nektr (‘nek-ter) , a Polygon-based token offering Web3 business and commerce solutions, announced the release of two new decentralized applications (dApps) as part of its recent rebranding.
  • Nektr is developing a Web3 Commerce Marketplace platform with P2P and B2P offerings, formally launching in Q2 or Q3 of 2024.
  • With advanced tools and dApps, the platform will provide a seamless and secure experience for creators, NFT collectors, crypto enthusiasts, consumers, and brands.
  • Fueling its growing ecosystem is NEKTR ($NKT), a governance token with multiple benefits for holders and consumers.

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Retrieved on: 
星期一, 三月 4, 2024
Oxygen, IPF, Idiopathic disease, Serum, Doctor of Philosophy, Blood, Homeostasis, Idiopathic pulmonary fibrosis, Inflammation, Vital signs, Safety, Health care, BAL, Biomarker, Pharmacokinetics, Patient, NKT, Natural killer T cell, Bronchoalveolar lavage, NIHR, Movement, GRI, CTA, Immune system, Pharmaceutical industry

LA JOLLA, CA, March 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.

Key Points: 
  • The MHRA is the UK regulatory authority, a government agency, for medicines and medical devices.
  • The MHRA is responsible for the regulation of medicines and medical devices and equipment used in healthcare and the investigation of harmful incidents.
  • “We are pleased to receive authorization from the MHRA and take a step in the global expansion of our clinical development for GRI-0621.
  • We are focused on driving this program forward and generating important data readouts this year,” Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

Frida Norrbom Sams and Mark Williamson proposed as new members of the board of directors of Concentric AB

Retrieved on: 
星期四, 二月 15, 2024
HVAC, Aereon, Concentric objects, Growth, KKR, Kohlberg Kravis Roberts, Ingersoll Rand, NKT, Husqvarna

REDDITCH, England, Feb. 15, 2024 /PRNewswire/ -- The nomination committee of Concentric AB proposes that Frida Norrbom Sams and Mark Williamson are elected as new members of the board of directors at the annual general meeting on April 18, 2024.

Key Points: 
  • REDDITCH, England, Feb. 15, 2024 /PRNewswire/ -- The nomination committee of Concentric AB proposes that Frida Norrbom Sams and Mark Williamson are elected as new members of the board of directors at the annual general meeting on April 18, 2024.
  • The nomination committee's proposal means the board will consist of eight members elected by the general meeting, with no deputies.
  • More detailed descriptions of Frida Norrbom Sams and Mark Williamson will be available on Concentric's website as soon as the notice to the 2024 annual general meeting has been published.
  • "With Frida Norrbom Sams' and Mark Williamson's robust industrial, financial and international experience and competence, they will contribute to the company's continued growth and value creation.

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Retrieved on: 
星期二, 二月 6, 2024
Prostate cancer, Investigational New Drug, Cytokine, Immunotherapy, SITC, Clinical trial, NK, Society, Patient, IND, Good, Death, TSX, Allele, NKT, Therapy, Vaccine, Good manufacturing practice, HLA, Cancer, GMP, BCT

We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Key Points: 
  • We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.
  • “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application.
  • BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines.
  • According to 2024 Cancer Facts & Figures , prostate cancer is projected to be the most common cancer among men in 2024.